7/20/2004 -- FDA APPROVES BOTOX® (Botulinum Toxin Type A) FOR TREATMENT OF SEVERE UNDERARM SWEATING
IRVINE, Calif. – July 20, 2004 – Allergan, Inc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved BOTOX® (botulinum toxin type A) for the treatment of severe primary axillary hyperhidrosis (severe underarm sweating) that is inadequately managed with topical agents. Primary axillary hyperhidrosis often goes undiagnosed, misdiagnosed and untreated due to lack of awareness on the part of the patients and physicians alike. “The FDA approval of BOTOX® for severe primary axillary hyperhidrosis that is inadequately managed with topical agents represents an important new treatment option for people living with this disease,” said Dr. Mitchell Brin, Senior Vice President of Development, BOTOX® and Neurology, Allergan, Inc. “It also marks another milestone in the history of BOTOX®, which continues to demonstrate its versatility in meeting patients’ medical needs.” Click here for more of this release